(Valneva) Three doses of inactivated Covid-19 vaccine of biotech company Valneva have been found to have an 87% effectiveness against the Omicron variant.
The vaccine candidate, VLA2001, which also carries neutralizing effects against the initial Covid-19 virus and the Delta variant, was tested on 30 participants.
Valneva found a mean fold reduction of neutralization in the Delta variant of 2.7 times and 16.7 times for Omicron, relative to the ancestral virus.
Chief Medical Officer at Valneva Juan Jaramillio says the company is pleased with the results as the vaccine advances an important component in the control of Covid-19.
The company now aims to continue providing data to the regulators to obtain the relevant approvals for the vaccine candidate in the first quarter of the year.
The development happens after, in November, Valneva agreed to supply up to 60 million doses of VLA2001 in two years to the EU, which includes 24.3 million doses this year. The company also has a one million doses supply agreement with the Kingdom of Bahrain in the first quarter of the year.
Stock reacts VLA: EPA is up +19.62%.
